Celsius Holdings Inc (CELH): “North America revenue increased 101% to...

“North America revenue increased 101% to $249 million,

Snizzle · 2023-05-10T01:03:06.8600000Z

“North America revenue increased 101% to $249 million, up from $124 million in Q1 2022” Ghee….I wonder why…..bang energy nearly out of business and Celsius SMASHING IT in North America. Must be some reason this is happening….lol!

Play Episode

4min

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

AuKing prepares for gold mining at Mt Freda site

AuKing Mining Ltd managing director Paul Williams talked with Proactive about the company's latest update on its Cloncurry Project in Queensland, focusing on the Mt Freda deposit. Williams confirmed that with Orion Resources nearing acquisition completion, AuKing is preparing to restart mining operations at the historical Mt Freda gold mine. Williams highlighted Mt Freda as a top target for redevelopment due to its existing mining lease and approvals, as well as a current resource estimate of around 100,000oz. "We really don't want to start a mining operation unless we've got reserves in the resource estimate," he explained, outlining the company’s aim to confirm and expand those figures through an upcoming drilling program. In addition to resource verification, AuKing is evaluating two processing options: existing vat leaching pits and a nearby cavern in-leach circuit at Lorena. Williams also noted the broader potential in the surrounding six square kilometre Mt Freda Complex, which contains multiple historical deposits, hinting at further exploration upside. Drilling is expected to start within weeks of the acquisition's financial close in April, with results anticipated in the months following. Williams described the program as "a fascinating exercise," indicating renewed momentum behind the restart strategy. For more updates from AuKing Mining Ltd and other resource sector insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #AuKingMining #MtFreda #GoldMining #ASXAKN #CloncurryProject #ResourceDrilling #MiningRestart #QueenslandMining #JuniorMining #GoldExploration #MiningInvestment #ASXResources #OrionResources

Proactive - Interviews for investors

Sprintex secures A$3.25m to expand global output; reduce debt

Sprintex Ltd (ASX:SIX) managing director and CEO Jay Upton talked with Proactive's Stephen Gunnion about the company’s successful A$3.25 million capital raise, drawing strong backing from both existing shareholders and new institutional investors. Upton said approximately A$1.5 million of the funds would go toward debt reduction, with the remaining A$1.75 million allocated to accelerating production and sales of Sprintex’s new range of high-speed electric compressors. These products aim to improve energy efficiency, offering “more than 50% energy savings versus the current benchmark products”. He discussed the company’s strategic manufacturing expansion, highlighting the transition of its Malaysian facility to support electric compressor production—mirroring current operations in Suzhou, China. This move is designed to double manufacturing capacity, navigate global trade sensitivities, and better serve regional preferences. Currently in the Netherlands, Upton also outlined a five-year partnership with Mest Water, a Dutch wastewater treatment firm focused on ammonia reduction in livestock manure—a project supported by the Dutch government. Sprintex will supply compressors for this initiative. Looking ahead, Sprintex is set to exhibit at the Hannover International Trade Fair in Germany, where the company expects to attract significant attention for its clean air and vacuum solutions across industries like aquaculture, semiconductors, textiles, and agriculture. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #Sprintex #CleanTech #IndustrialCompressors #EnergyEfficiency #GreenTechnology #CapitalRaise #Manufacturing #DutchTech #HannoverFair #VacuumTechnology #AsiaManufacturing #SustainableIndustry #AmmoniaReduction #ElectricCompressors

Followers	274
Posts	33802
Boards Moderated	1
Alias Born	03/11/2011

Volume:	2,372
Day Range:
Bid:	35.52
Ask:	35.71
Last Trade Time:	5:20:15 AM EDT
Total Trades:	37

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CELH Detailed Quote

Recent CELH News

More CELH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent CELH News

Go Ad-Free